What is the recommended dosing of Alteplase (tissue plasminogen activator) for fibrinolysis in acute myocardial infarction (MI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosing of Alteplase for Fibrinolysis in Acute Myocardial Infarction

For patients with acute myocardial infarction requiring fibrinolysis, Alteplase should be administered as a 15 mg intravenous bolus, followed by 0.75 mg/kg over 30 minutes (up to 50 mg), then 0.5 mg/kg over 60 minutes (up to 35 mg), with a total dose not exceeding 100 mg. 1

Dosing Regimen Details

  • Initial dose: 15 mg IV bolus 1
  • Second phase: 0.75 mg/kg over 30 minutes (maximum 50 mg) 1
  • Third phase: 0.5 mg/kg over 60 minutes (maximum 35 mg) 1
  • Total maximum dose: 100 mg 1
  • Required adjunctive therapy: Intravenous heparin for 24 to 48 hours 1

Adjunctive Antithrombotic Therapy

Antiplatelet Therapy

  • Aspirin: Starting dose of 150-500 mg orally or 250 mg IV if oral ingestion is not possible 1
  • Clopidogrel: Loading dose of 300 mg orally if aged ≤75 years, followed by maintenance dose of 75 mg/day 1

Anticoagulation

  • Unfractionated heparin: 60 U/kg IV bolus (maximum 4000 U) followed by IV infusion of 12 U/kg/hour (maximum 1000 U/hour) for 24-48 hours 1
    • Target aPTT: 50-70 seconds or 1.5-2.0 times control 1
    • Monitor aPTT at 3,6,12, and 24 hours 1
  • Enoxaparin (preferred over UFH): 1
    • For patients <75 years: 30 mg IV bolus followed 15 minutes later by 1 mg/kg SC every 12 hours
    • For patients >75 years: No IV bolus; start with first SC dose of 0.75 mg/kg (maximum 75 mg for first two doses)
    • For patients with creatinine clearance <30 mL/min: SC doses given once every 24 hours

Clinical Considerations

  • Alteplase is a fibrin-specific agent and is recommended over non-fibrin specific agents like streptokinase 1
  • Fibrinolysis should be initiated within 12 hours of symptom onset 1
  • Fibrinolysis is recommended when primary PCI cannot be performed by an experienced team within 120 minutes of first medical contact 1
  • In patients presenting early (<2 hours after symptom onset) with a large infarct and low bleeding risk, fibrinolysis should be considered if time from first medical contact to balloon inflation is >90 minutes 1

Post-Fibrinolysis Management

  • Transfer to a PCI-capable center following fibrinolysis is indicated in all patients 1
  • Rescue PCI is indicated immediately if fibrinolysis fails (<50% ST-segment resolution at 60 minutes) 1
  • Emergency PCI is indicated for recurrent ischemia or evidence of reocclusion after initially successful fibrinolysis 1
  • Optimal timing of angiography for stable patients after successful lysis: 3-24 hours 1

Common Pitfalls and Caveats

  • Do not exceed the maximum total dose of 100 mg 1
  • Alteplase requires adjunctive IV heparin therapy for 24-48 hours 1
  • Unlike streptokinase, Alteplase does not result in antibody formation and can be re-administered if needed 1
  • Careful monitoring of aPTT is essential when using heparin; values >70 seconds are associated with increased risk of bleeding, reinfarction, and death 1
  • The risk of hemorrhagic stroke is higher with Alteplase than with streptokinase 2
  • Tenecteplase, aspirin, enoxaparin, and clopidogrel comprise the most extensively studied antithrombotic combination for a pharmacoinvasive strategy 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.